Navigation Links
Favrille CEO to Present at Bear Stearns Healthcare Conference
Date:9/4/2007

Live Webcast from the Grand Hyatt New York on Monday, September 10th

SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will present at the Bear Stearns 20th Annual Healthcare Conference at 1:30 p.m. Eastern time on Monday, September 10, 2007. The conference will be held at the Grand Hyatt New York.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)

Dr. Longenecker will provide an overview of Favrille and the clinical trials of its lead compound, FavId(R), which is currently in a pivotal Phase 3 clinical trial for the treatment of follicular B-cell non-Hodgkin's lymphoma (NHL). A live webcast of the presentation can be accessed at http://www.favrille.com. The replay will be available approximately one hour after the presentation and will be archived until October 10, 2007.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, ,Primaryefficacyendpointhasbeenmetforpatien... , QUEBECCITY,Nov.24/PRNewswire-FirstCall/-AE...ny"),aglobalbiopharmaceuticalcompanyfocusedonendoc...acydatafromaPhase2studywithitstargetedcytotoxicpep...ithadvancedorrecurrentendometrialcancer.Inapersona...
(Date:11/24/2009)...,, REDWOODCITY,Calif.,Nov.24/PRNewswire-First...ncedthatRandyScott,GenomicHealth,sExecutiveChairma...ConferenceinNewYorkCityonTuesday,December1,2009at1...chivedwebcastofthepresentation,visittheInvestorRel...estor.genomichealth.com .Pleaseconnecttothewebsite...
(Date:11/24/2009)...,, SEATTLE,Nov.24/PRNewswire-FirstCall/--Cell...twillpresentatthe21stAnnualPiperJaffrayHealthCareC...attheNewYorkPalaceHotel. ,, CTIwillpresentonTue...loor).AliveaudiowebcastofCTI,spresentationwillbeav...eavailableforreplayafterwards. , ,PiperJaffrayHea...
(Date:11/23/2009)... Graphene consists of a two-dimensional carbon la...xagonal lattice, resembling a honeycomb. Carbon na...k piles of graphene sheets form graphite. Graphene...xtremely tear-resistant, an excellent thermal cond...s brittleness and ductility. In addition, graphene...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2Polymer with honeycomb structure 2
...er a Personal Health Record and A Year,s Supply of...Kissably Sweet at the White House , , LOS ANGELES...letin Board: FVRL), which through its wholly-owned...lectively, "MMR") provides consumer-controlled Per...ds.com ) and electronic safe deposit box storage s...
...rm launch will Enable 60,000+ Researchers at 38 In...rch 3 Collexis Holdings Inc. (OTC Bulletin Board:...d knowledge discovery software, announced today th...lational Research drawing on the research profile...fe science researchers. The platform is available ...
...intelligence in 2 hours , , CHICAGO, March 27 ...ader in rapid microbial detection solutions for in...(TM), the first easy-to-use RNA-based assay for de...tively without the need for expensive equipment or...rmaceutical, beauty and home care products using C...
Other Biology Technology:MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research 2Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research 3Collexis Connects Biomedical Researchers and Clinical Scientists with the Collexis Expert Platform for Translational Research 4Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays 2Celsis Introduces ReACT(TM) RNA-Based Microbial Detection Assays 3
(Date:11/25/2009)... NOVEMBER 25, 2009 Soil is the linchpin of the en...phere meet. Despite that, many students see soil a... more. Soil science educators are challenged with ...ize the critical importance of soil in the environ... and earth science teachers at University of Nebra...
(Date:11/25/2009)...te University assistant professors recently receiv...SF) to continue research beneficial to understandi...0. , Christopher Blackwood, assistant professor ...ded grants to support two separate research projec...er Decomposer Communities and Functions from the L...
(Date:11/24/2009)...s of years it has been prescribed by traditional h... headaches and stomach pain to fever and flu. , N...iversity have been able to scientifically prove th...therwise known as Brazilian mint. , Testing this ...by researcher Graciela Rocha was able to show that...
Breaking Biology News(10 mins):It's not just dirt! 2Kent State University professors focus research on the environment with grants totaling $890,000 2Got a pain? -- Have a cup of Brazilian mint 2FertilityAuthority Introduces E Newsletter The Daily Shot 51744 1FertilityAuthority Introduces E Newsletter The Daily Shot 51744 2Snoring Isn 26apos 3Bt Sexy LLC Announces Professional Relationship with the American Sleep Apnea Association 51742 1Snoring Isn 26apos 3Bt Sexy LLC Announces Professional Relationship with the American Sleep Apnea Association 51742 2Marathon Health Adds Fitness Center Capability Medically based Fitness Centers Show Improved Engagement and Efficacy 51739 1Marathon Health Adds Fitness Center Capability Medically based Fitness Centers Show Improved Engagement and Efficacy 51739 2Marathon Health Adds Fitness Center Capability Medically based Fitness Centers Show Improved Engagement and Efficacy 51739 3
...ugs against cancer is cisplatin because it attache...lso kills healthy tissue. Many scientists are crea...empts to find treatments without side effects. One... drugs, or photodynamic therapy (PDT). Now a Virgi...been working on both non-cisplatin drugs and cispl...
...ete tumor removal at breast cancer excision is int...rs used light waves in a newly explored region of ...--to examine excised breast tissue and determine i... with good results. This technology has the potent...nd tissue samples to get clear surgical margins. ,...
...m The American Naturalist, biologists from the Uni...or more than two decades to explore a longstanding... laid by a female bird ?known as "clutch size" ?ch...ensive debate in the literature…was first focused ...lutch size differ from the most productive clutch ...
Other Biology News:Light activated anticancer drug targeted to DNA using cisplatin like sub-units 2Terahertz imaging may reduce breast cancer surgeries 2
...) Thermo Scientific (Part of Thermo Fisher Scienti...n, introduces the latest product innovation for la...liability and performance platform of Thermo's DSQ...es the new DynaMax XR ion detection system and the...
Murashige and Skoog Basal Medium with Gamborg's Vitamins from Sigma-Aldrich
...dization chamber assembly (1 each) Components (ch...rray chamber user guide plastic tweezersChambers ... and reused. The chamber is designed for use with ...tom oligo microarrays, in conjunction with Agilent...
Iscove's Modified Dulbecco's Medium (IMDM) from Sigma-Aldrich
Biology Products: